Identification

Name
Glycerin
Accession Number
DB09462  (EXPT01027, DB04077)
Type
Small Molecule
Groups
Approved, Investigational
Description

A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.

Structure
Thumb
Synonyms
  • 1,2,3-propanetriol
  • 1,2,3-trihydroxypropane
  • Glycerin, anhydrous
  • Glycerin,anhydrous
  • Glycerine
  • glycérine
  • Glycerinum
  • Glycerol
  • glycérol
  • Glyzerin
  • Monoctanoin component D
  • Ölsüß
  • Propanetriol
  • Trihydroxypropane
External IDs
E-422 / Fema no. 2525 / INS No.422 / INS-422 / M 314429 / NSC-9230 / PZN 7474853
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Coca-Glycerine ControlInjection, solution.525 mL/mLIntradermalAntigen Laboratories, Inc.1974-03-23Not applicableUs
Glycerol-Saline ControlInjection.53 g/mLCutaneous; Intradermal; SubcutaneousAllermed Laboratories, Inc.1974-03-12Not applicableUs
Negative Skin Test Control - GlycerinLiquid50 %PercutaneousJubilant Hollisterstier LlcNot applicableNot applicableCanada
Sterile Diluent for Allergenic ExtractInjection, solution.5 mL/mLIntradermal; SubcutaneousAntigen Laboratories, Inc.1974-03-23Not applicableUs
Synovisol Irrigation Solution 2.6%Solution2.6 %IrrigationBaxter Laboratories1996-09-26Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DyNAmic KitKitOral; TopicalAlvix Laboratories2015-04-172018-03-12Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
3 en 1 Cleanser. Deep CleansingLiquid13 mg/mLTopicalCasmara Cosmetics, Sa2016-06-06Not applicableUs
3 en 1 Cleanser. Deep CleansingLiquid13 mg/mLTopicalCasmara Cosmetics, Sa2016-06-06Not applicableUs
75% Olive Oil MarseilleSoap15 g/100gTopicalInternational Nature Soap Institute2015-06-17Not applicableUs
Ab Duo Whitening ASolution10 g/100mLTopicalGeneral Bio Co., Ltd.2014-12-08Not applicableUs
Ac AllLiquid2 g/100mLTopicalGl Bio Tech2014-10-17Not applicableUs
Actifirm Recovery Toner Gowoonsesang ExpertCream28 mL/140mLCutaneousGOWOONSESANG COSMETICS CO., LTD.2010-06-012018-02-20Us
Active ResurgenceCream.08 g/gTopicalAmi Cosmetic Co.,Ltd.2013-08-01Not applicableUs
Active Resurgence EyeCream.07 mg/mLTopicalAmi Cosmetic Co.,Ltd.2013-08-01Not applicableUs
Active Resurgence SerumLiquid.08 mg/mLTopicalAmi Cosmetic Co.,Ltd.2013-08-01Not applicableUs
Active Resurgence TonerLiquid.08 mg/mLTopicalAmi Cosmetic Co.,Ltd.2013-08-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Redness ReliefGlycerin (.0025 mg/mL) + Naphazoline hydrochloride (.00012 mg/mL)Solution / dropsOphthalmic7 Select, Inc2017-03-28Not applicableUs
AdipoWinGlycerin (60 mg/mL) + Dimethicone (5 mg/mL)CreamTopicalSupadelixir Co Ltd2017-01-02Not applicableUs
Advanced Eye Relief Dry Eye RejuvenationGlycerin (3 mg/mL) + Propylene glycol (10 mg/mL)Solution / dropsOphthalmicBauch & Lomb Incorporated2010-09-01Not applicableUs
Agarol Eml StrawberryGlycerin (200 mg) + Mineral oil (1.6 ml) + Phenolphthalein (65 mg)EmulsionOralWarner Lambert Canada Inc.1992-12-311997-09-15Canada
Agarol PlainGlycerin (800 mg) + Mineral oil (1.6 ml)EmulsionOralNumark Laboratories, Inc.1998-11-302016-06-02Canada
Agarol Plain EmlGlycerin (800 mg) + Mineral oil (1.6 ml)EmulsionOralWarner Lambert Canada Inc.1992-12-311998-08-17Canada
Agarol Vanilla Laxative LiqGlycerin (200 mg) + Mineral oil (1.6 ml) + Phenolphthalein (65 mg)LiquidOralWarner Lambert Canada Inc.1992-12-311997-09-15Canada
Aloe Vera GelGlycerin (10 g/100g) + Propylene glycol (4 g/100g)GelTopicalNINGBO JIANGBEI OCEAN STAR TRADING CO.,LTD2015-02-20Not applicableUs
Aloe Vera SprayerGlycerin (4 g/100g) + Aloe Vera Leaf (2 g/100g) + Propylene glycol (2 g/100g) + Tocopherol (.5 g/100g)LiquidTopicalNINGBO JIANGBEI OCEAN STAR TRADING CO.,LTD2015-02-20Not applicableUs
Aqua-ear DpsGlycerin (5 %) + Isopropyl Alcohol (95 %)Solution / dropsAuricular (otic)All Star Sales and Service Ltd.1992-12-312001-06-21Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2x First EssenceGlycerin (4 g/200mL)CreamTopicalTonymoly Co., Ltd.2016-05-01Not applicableUs
3ce Liqu Id Eye Liner BlackGlycerin (.19 g/6.5g)LiquidTopicalNanda Co., Ltd.2016-08-01Not applicableUs
3ce Liqu Id Eye Liner BrownGlycerin (.19 g/6.5g)LiquidTopicalNanda Co., Ltd.2016-08-01Not applicableUs
3D LiftingGlycerin (.067 mL/2mL)LiquidTopicalBabor Cosmetics America, Corp.2009-06-012017-07-15Us
AC Clear Sheet MaskGlycerin (1.84 g/23mL)PatchTopicalMiguhara2016-01-02Not applicableUs
AC Control Daily MaskGlycerin (1.8 g/101)SolutionTopicalModecos Co., Ltd.2016-02-01Not applicableUs
Advanced DNA Medicated CollectionGlycerin + Lidocaine hydrochlorideKitOral; TopicalAsclemed Usa, Inc1995-07-10Not applicableUs
Advanced DNA Medicated Collection Kit IIGlycerin + Lidocaine hydrochlorideKitOral; TopicalAsclemed Usa, Inc.2014-02-04Not applicableUs
Advanced DNA Medicated Collection Kit IIIGlycerin + Lidocaine hydrochlorideKitOral; TopicalAsclemed Usa, Inc.2014-02-04Not applicableUs
All In One Multi Foam CleanserGlycerin (6 mg/150mL)GelTopicalWow Ventures2015-05-012017-08-11Us
Categories
UNII
PDC6A3C0OX
CAS number
56-81-5
Weight
Average: 92.0938
Monoisotopic: 92.047344122
Chemical Formula
C3H8O3
InChI Key
PEDCQBHIVMGVHV-UHFFFAOYSA-N
InChI
InChI=1S/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2
IUPAC Name
propane-1,2,3-triol
SMILES
OCC(O)CO

Pharmacology

Indication

It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent.

Associated Conditions
Pharmacodynamics

Glycerin is commonly classified as an osmotic laxative but may act additionally or alternatively through its local irritant effects; it may also have lubricating and fecal softening actions. Glycerin suppositories usually work within 15 to 30 minutes.

Mechanism of action

When administered rectally, glycerin exerts a hygroscopic and/or local irritant action, drawing water from the tissues into the feces and reflexively stimulating evacuation. Glycerin decreases intraocular pressure by creating an osmotic gradient between the blood and intraocular fluid, causing fluid to move out of the aqueous and vitreous humors into the bloodstream.

TargetActionsOrganism
APeroxisome proliferator-activated receptor delta
agonist
Human
UHematopoietic prostaglandin D synthaseNot AvailableHuman
UEndoglucanase GNot AvailableClostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)
UGlutathione S-transferase PNot AvailableHuman
UGroup IIE secretory phospholipase A2Not AvailableHuman
UInositol-3-phosphate synthase 1Not AvailableHuman
UC4-dicarboxylate transport transcriptional regulatory protein DctDNot AvailableEnsifer meliloti
UAlcohol dehydrogenase 1BNot AvailableHuman
UInositol 1,4,5-trisphosphate receptor type 1Not AvailableHuman
UGlycodelinNot AvailableHuman
UAlpha-N-acetylgalactosaminidaseNot AvailableHuman
UCytochrome c4Not AvailablePseudomonas stutzeri
UBacterioferritinNot AvailableDesulfovibrio desulfuricans (strain ATCC 27774 / DSM 6949)
UTGF-beta receptor type-2Not AvailableHuman
UArgininosuccinate synthaseNot AvailableEscherichia coli (strain K12)
UEnolaseNot AvailableEnterococcus hirae
UADP-ribosylation factor 1Not AvailableHuman
UMultidrug resistance protein MexANot AvailablePseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
UBifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1Not AvailableHuman
UHistidinol dehydrogenaseNot AvailableEscherichia coli (strain K12)
UDNA mismatch repair protein MutLNot AvailableEscherichia coli (strain K12)
UGlycerol uptake facilitator proteinNot AvailableEscherichia coli (strain K12)
URibonucleoside-diphosphate reductase 1 subunit betaNot AvailableEscherichia coli (strain K12)
UA/G-specific adenine glycosylaseNot AvailableEscherichia coli (strain K12)
UtRNA (cytosine(38)-C(5))-methyltransferaseNot AvailableHuman
Absorption

Well absorbed orally, poorly absorbed rectally. Studies in humans and animals indicate glycerol is rapidly absorbed in the intestine and the stomach

Volume of distribution

Glycerin is distributed throughout the blood. Although glycerin generally does not appear in ocular fluids, it may enter the orbital sac when the eye is inflamed, with a consequent decrease in osmotic effect.

Protein binding
Not Available
Metabolism

Glycerin is a precursor for synthesis of triacylglycerols and of phospholipids in the liver and adipose tissue. When the body uses stored fat as a source of energy, glycerol and fatty acids are released into the bloodstream. Circulating glycerin does not glycate proteins as do glucose or fructose, and does not lead to the formation of advanced glycation endproducts (AGEs). In some organisms, the glycerin component can enter the glycolysis pathway directly and, thus, provide energy for cellular metabolism (or, potentially, be converted to glucose through gluconeogenesis). Before glycerol can enter the pathway of glycolysis or gluconeogenesis (depending on physiological conditions), it must be converted to their intermediate glyceraldehyde 3-phosphate. Glycerol metabolism is regulated by the enzymes glycerol kinase, (cytosolic) NAD+-dependent G3P dehydrogenase and (mitochondrial) FAD-linked G3P dehydrogenase.

Route of elimination

Approx 7-14% of dose is excreted unchanged in the urine within 2.5 hr.

Half life

30 - 45 minutes

Clearance
Not Available
Toxicity

Glycerol has very low toxicity when ingested ; Rat LD50 (oral)-12600mg/kg Mice LD50 (oral )-4090mg/kg Human TDLo (oral) - 1428mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe therapeutic efficacy of Glycerin can be decreased when used in combination with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Glycerin.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Glycerin.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Glycerin.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Glycerin.Approved, Vet Approved
AclidiniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aclidinium.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Glycerin.Approved
AgmatineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Agmatine.Experimental, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Glycerin.Experimental, Investigational
AlfentanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Glycerin.Approved, Investigational
AlmasilateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Almasilate.Approved, Experimental
AloglutamolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aloglutamol.Approved
AlphacetylmethadolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Alphaprodine.Illicit
Aluminium acetoacetateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aluminium acetoacetate.Experimental
Aluminium glycinateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aluminium glycinate.Experimental
Aluminum hydroxideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Glycerin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Glycerin.Approved
AmiodaroneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Amiodarone.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Amitriptyline.Approved
AmlodipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Amlodipine.Approved
AmoxapineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Amoxapine.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Glycerin.Approved, Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Anisotropine Methylbromide.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Glycerin.Approved
AranidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aranidipine.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Glycerin.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Glycerin.Approved, Nutraceutical
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Glycerin.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Glycerin.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Glycerin.Approved
AtropineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Atropine.Approved, Vet Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Glycerin.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Glycerin.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Azelnidipine.Approved, Investigational
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Glycerin.Investigational
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Glycerin.Approved, Investigational
BarnidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Barnidipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Glycerin.Approved, Investigational
BenactyzineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Benactyzine.Withdrawn
BencyclaneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Glycerin.Approved
BenidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Benidipine.Approved, Investigational
BenzatropineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Benzatropine.Approved
BenziloneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Benzilone.Experimental
BenzquinamideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Benzquinamide.Withdrawn
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Glycerin.Approved
BepridilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Glycerin.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bevonium.Experimental
BezitramideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bioallethrin.Approved, Experimental
BiperidenThe therapeutic efficacy of Glycerin can be decreased when used in combination with Biperiden.Approved, Investigational
BornaprineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bornaprine.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Glycerin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Glycerin.Approved, Investigational
BrinzolamideThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Glycerin.Approved
BromotheophyllineThe risk or severity of adverse effects can be increased when Bromotheophylline is combined with Glycerin.Approved
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Glycerin.Approved, Investigational
BrompheniramineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Brompheniramine.Approved
BuclizineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Buclizine.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Glycerin.Approved
BuprenorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Butylscopolamine.Approved, Investigational, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Glycerin.Approved
Calcium CarbonateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium silicateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Calcium silicate.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Glycerin.Experimental
CamylofinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Camylofin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Glycerin.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Canrenoic acid is combined with Glycerin.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Canrenone is combined with Glycerin.Investigational
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Glycerin.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Glycerin can be decreased when used in combination with Carboxyamidotriazole.Investigational
CarfentanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Carfentanil.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Glycerin.Approved, Investigational
CaroverineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Caroverine.Experimental
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Glycerin.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Glycerin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Glycerin.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Glycerin.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Glycerin.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Glycerin.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Chlorphenoxamine.Withdrawn
ChlorpromazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Glycerin.Approved
CicletanineThe risk or severity of adverse effects can be increased when Cicletanine is combined with Glycerin.Investigational
CilnidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Glycerin.Approved, Investigational
CinnarizineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cinnarizine.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Glycerin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Glycerin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Glycerin.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Glycerin.Approved
ClevidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Clevidipine.Approved, Investigational
ClidiniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Glycerin.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Clofenamide is combined with Glycerin.Experimental
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Glycerin.Approved
ClopamideThe risk or severity of adverse effects can be increased when Clopamide is combined with Glycerin.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Glycerin.Approved
ClorexoloneThe risk or severity of adverse effects can be increased when Clorexolone is combined with Glycerin.Experimental
ClozapineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Clozapine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Glycerin.Approved, Investigational
CocaineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Glycerin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Glycerin.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Glycerin.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Glycerin.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Glycerin.Approved
CurcuminThe serum concentration of Curcumin can be increased when it is combined with Glycerin.Approved, Investigational
CyclandelateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cyclandelate.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Glycerin.Experimental
CyclopentolateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cyclopentolate.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Glycerin.Approved
CycrimineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cycrimine.Approved
CyproheptadineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cyproheptadine.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Glycerin.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Glycerin.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Glycerin.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Glycerin.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Glycerin.Approved
DarifenacinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Darifenacin.Approved, Investigational
DarodipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Darodipine.Experimental
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Glycerin.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Glycerin.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Glycerin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Glycerin.Approved, Investigational
DesipramineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Desipramine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
DexetimideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dexetimide.Withdrawn
DexniguldipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dexniguldipine.Experimental
DextromoramideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dexverapamil.Experimental
DezocineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dezocine.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Glycerin.Approved, Illicit, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Glycerin.Approved, Investigational
DicyclomineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dicyclomine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glycerin.Approved, Investigational
DifemerineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Difemerine.Experimental
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Glycerin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Glycerin.Approved
DihexyverineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dihexyverine.Experimental
DihydrocodeineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Glycerin.Approved, Investigational
DimetindeneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dimetindene.Approved, Investigational
DiphemanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphemanil.Experimental
Diphemanil MethylsulfateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphenhydramine.Approved, Investigational
DiphenidolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphenoxylate.Approved, Illicit
DisopyramideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Glycerin.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Glycerin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Glycerin.Approved
DosulepinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dosulepin.Approved
DotarizineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Dotarizine.Investigational
DoxepinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Glycerin.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
DoxylamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Doxylamine.Approved, Vet Approved
DPDPEThe therapeutic efficacy of Glycerin can be decreased when used in combination with DPDPE.Experimental
DrospirenoneThe risk or severity of adverse effects can be increased when Drospirenone is combined with Glycerin.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Glycerin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Glycerin.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Glycerin.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Glycerin.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Glycerin.Approved, Investigational
EluxadolineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Eluxadoline.Approved, Investigational
EmeproniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Emepronium.Experimental
EmopamilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Glycerin.Approved
EperisoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Eperisone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Glycerin.Approved, Investigational
EpitizideThe risk or severity of adverse effects can be increased when Epitizide is combined with Glycerin.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Glycerin.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Glycerin.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Glycerin.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Glycerin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Glycerin.Approved, Investigational
EtanautineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Etanautine.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Glycerin.Approved
EthopropazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ethosuximide.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Glycerin.Withdrawn
EthylmorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ethylmorphine.Approved, Illicit
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Glycerin.Approved
EtorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Etorphine.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Etybenzatropine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Glycerin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Glycerin.Approved
FelodipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fendiline.Withdrawn
FenpiveriniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fenpiverinium.Experimental
FenquizoneThe risk or severity of adverse effects can be increased when Fenquizone is combined with Glycerin.Experimental
FentanylThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fesoterodine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Glycerin.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Glycerin.Approved
Fish oilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fish oil.Approved, Nutraceutical
FlavoxateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Flavoxate.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Glycerin.Approved
FlunarizineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Flunarizine.Approved
FlupentixolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Fluspirilene.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Glycerin.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Glycerin.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Glycerin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Glycerin.Approved, Vet Approved
GabapentinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Gabapentin.Approved, Investigational
Gallamine TriethiodideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Gallamine Triethiodide.Approved
GallopamilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Glycerin.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Glycerin.Approved, Investigational
GlycopyrroniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Glycerin.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Glycerin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Glycerin.Approved, Investigational, Withdrawn
HeroinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Heroin.Approved, Illicit, Investigational
HexocycliumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hexocyclium.Approved
HomatropineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Homatropine.Approved
Homatropine MethylbromideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Homatropine Methylbromide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Glycerin.Approved, Vet Approved
HydrocodoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Glycerin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Glycerin.Approved, Investigational
HydromorphoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hydromorphone.Approved, Illicit
HydrotalciteThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hydrotalcite.Approved, Experimental, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Glycerin.Approved
HyoscyamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Hyoscyamine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Ibopamine is combined with Glycerin.Experimental
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Glycerin.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Glycerin.Approved
ImidafenacinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Imidafenacin.Approved, Investigational
ImipramineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Glycerin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Glycerin.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Glycerin.Approved
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glycerin.Approved, Investigational
IpratropiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ipratropium.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Glycerin.Approved, Investigational
IsopropamideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Isopropamide.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Isosorbide is combined with Glycerin.Approved, Investigational
IsradipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Glycerin.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Glycerin.Approved, Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Glycerin.Approved
KetobemidoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Glycerin.Approved, Investigational
LacidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lacidipine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Glycerin.Approved, Investigational
LamotrigineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Glycerin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Glycerin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Glycerin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Glycerin.Approved, Investigational
LercanidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Glycerin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Glycerin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Glycerin.Approved, Investigational
Levomethadyl AcetateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Glycerin.Approved, Investigational
LevorphanolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Levorphanol.Approved
LidoflazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lidoflazine.Experimental
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Glycerin.Approved
LofentanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lofentanil.Illicit
LomerizineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lomerizine.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Glycerin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Glycerin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Glycerin.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Glycerin.Approved, Investigational
MagaldrateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Magaldrate.Approved, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Glycerin.Approved, Investigational
MaprotilineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Maprotiline.Approved, Investigational
MazaticolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mazaticol.Experimental
MebeverineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mebeverine.Approved, Investigational
MebutizideThe risk or severity of adverse effects can be increased when Mebutizide is combined with Glycerin.Experimental
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Glycerin.Approved, Investigational
MefrusideThe risk or severity of adverse effects can be increased when Mefruside is combined with Glycerin.Experimental
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Glycerin.Approved
MentholThe therapeutic efficacy of Glycerin can be decreased when used in combination with Menthol.Approved
MepenzolateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mepenzolate.Approved
MeptazinolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Mersalyl is combined with Glycerin.Approved
MethadoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methadyl Acetate.Approved, Illicit
MethanthelineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Glycerin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Glycerin.Approved
MethotrimeprazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethscopolamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methscopolamine.Approved
MethsuximideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Glycerin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Glycerin.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Methylscopolamine bromide.Approved
MeticraneThe risk or severity of adverse effects can be increased when Meticrane is combined with Glycerin.Experimental
MetixeneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Metixene.Approved
MetocurineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Metocurine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Glycerin.Approved
MibefradilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mibefradil.Investigational, Withdrawn
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Glycerin.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Glycerin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Glycerin.Approved, Investigational
MivacuriumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Mivacurium.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Glycerin.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
MuzolimineThe risk or severity of adverse effects can be increased when Muzolimine is combined with Glycerin.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glycerin.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Glycerin.Approved
NaftopidilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Naftopidil.Investigational
NalbuphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Glycerin.Approved
NaltrexoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Glycerin.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Glycerin.Approved, Vet Approved
NicardipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nicardipine.Approved, Investigational
NicomorphineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nicomorphine.Experimental
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Glycerin.Approved
NiguldipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Glycerin.Approved, Investigational
NiludipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Glycerin.Approved
NisoldipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nitrendipine.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Glycerin.Approved
NormethadoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Normethadone.Approved, Illicit
NortriptylineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nylidrin.Approved
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Glycerin.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Glycerin.Investigational
OlanzapineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Olanzapine.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Glycerin.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Glycerin.Approved
OpiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Opium.Approved, Illicit
OrphenadrineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Orphenadrine.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Glycerin.Approved
OtiloniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Otilonium.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxitropium.Investigational
OxybutyninThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphencyclimineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxyphencyclimine.Approved
OxyphenoniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Oxyphenonium.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Glycerin.Approved, Vet Approved
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Glycerin.Approved
PancuroniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Glycerin.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Glycerin.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Glycerin.Approved, Investigational
ParoxetineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Glycerin.Approved
PenfluridolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Penfluridol.Experimental
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Glycerin.Approved, Vet Approved
PenthienateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Penthienate.Experimental
PethidineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pethidine.Approved
PhenazocineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Phenazocine.Experimental
PhenglutarimideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Phenglutarimide.Experimental
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Glycerin.Approved, Investigational
PhenoperidineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Phenoperidine.Experimental
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Glycerin.Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Glycerin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Glycerin.Approved, Investigational
PinaveriumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pinaverium.Approved
PipecuroniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pipecuronium.Approved
PipenzolateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pipenzolate.Experimental
PiperidolateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Piperidolate.Experimental
PirenzepineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pirenzepine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Glycerin.Approved
PiritramideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Piritramide.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Glycerin.Approved
PizotifenThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pizotifen.Approved
PoldineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Poldine.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Glycerin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Glycerin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Glycerin.Approved, Investigational
PotassiumThe risk or severity of adverse effects can be increased when Potassium is combined with Glycerin.Approved, Experimental
Potassium cationThe risk or severity of adverse effects can be increased when Potassium cation is combined with Glycerin.Approved, Investigational
Potassium CitrateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Glycerin.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Glycerin.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Glycerin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Glycerin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Glycerin.Approved, Vet Approved
PrenylamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Prenylamine.Withdrawn
PrifiniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Prifinium.Experimental
ProcyclidineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Procyclidine.Approved
PromazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Promethazine.Approved, Investigational
PropanthelineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Propantheline.Approved
PropiomazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Propiverine.Approved, Investigational
PropranololThe serum concentration of Propranolol can be increased when it is combined with Glycerin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Glycerin.Approved
QuetiapineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Glycerin.Approved
QuinidineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Quinidine.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Glycerin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Glycerin.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Rapacuronium.Withdrawn
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Glycerin.Approved
RemifentanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Remifentanil.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Glycerin.Approved, Investigational
RevefenacinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Revefenacin.Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Glycerin.Experimental
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Glycerin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Glycerin.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Glycerin.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Glycerin.Approved
RociverineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Rociverine.Experimental
RocuroniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Rocuronium.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Rolofylline is combined with Glycerin.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Glycerin.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Glycerin.Approved, Investigational
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Glycerin.Approved, Investigational
ScopolamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Scopolamine.Approved, Investigational
SeletracetamThe therapeutic efficacy of Glycerin can be decreased when used in combination with Seletracetam.Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Glycerin.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Glycerin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Glycerin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Glycerin.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Glycerin.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Glycerin.Approved, Investigational
Sodium tartrateThe therapeutic efficacy of Glycerin can be decreased when used in combination with Sodium tartrate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Glycerin.Approved
SolifenacinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Solifenacin.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Glycerin.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Glycerin.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Glycerin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Glycerin.Experimental
SpiradolineThe risk or severity of adverse effects can be increased when Spiradoline is combined with Glycerin.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Glycerin.Approved
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Glycerin.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Glycerin.Experimental
SufentanilThe therapeutic efficacy of Glycerin can be decreased when used in combination with Sufentanil.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Glycerin.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Glycerin.Approved, Investigational
TacrineThe serum concentration of Tacrine can be increased when it is combined with Glycerin.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Glycerin.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Glycerin.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Glycerin.Approved
TapentadolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tapentadol.Approved
Tartaric acidThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tartaric acid.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Glycerin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glycerin.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Glycerin.Approved, Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Glycerin.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Glycerin.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Glycerin.Approved, Withdrawn
TerodilineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Terodiline.Experimental
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Glycerin.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Glycerin.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tetrahydropalmatine.Investigational
TetrandrineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tetrandrine.Experimental
TheobromineThe risk or severity of adverse effects can be increased when Theobromine is combined with Glycerin.Approved, Investigational
ThonzylamineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Thonzylamine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Glycerin.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Ticrynafen is combined with Glycerin.Withdrawn
Tiemonium iodideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tiemonium iodide.Experimental
TilidineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tilidine.Experimental
TimepidiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Timepidium.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Glycerin.Approved
TiotropiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tiotropium.Approved
Tolfenamic AcidThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolterodineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tolterodine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Glycerin.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Glycerin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Glycerin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Glycerin.Approved
TramadolThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tramadol.Approved, Investigational
TranilastThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tranilast.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Glycerin.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Glycerin.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Glycerin.Approved, Vet Approved
TridihexethylThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tridihexethyl.Withdrawn
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Glycerin.Approved, Investigational
TriflupromazineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Glycerin can be decreased when used in combination with Trihexyphenidyl.Approved
TrimebutineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Glycerin can be decreased when used in combination with Trimethadione.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Glycerin.Approved
TropatepineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tropatepine.Experimental
TropicamideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Tropicamide.Approved, Investigational
TrospiumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Trospium.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Glycerin.Approved, Investigational, Nutraceutical
UlaritideThe risk or severity of adverse effects can be increased when Ularitide is combined with Glycerin.Investigational
UmeclidiniumThe therapeutic efficacy of Glycerin can be decreased when used in combination with Umeclidinium.Approved
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Glycerin.Experimental
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Glycerin.Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Glycerin.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Glycerin.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Glycerin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Glycerin.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Glycerin.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Glycerin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Glycerin.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Glycerin.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Glycerin.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Glycerin.Approved, Investigational
VinpocetineThe therapeutic efficacy of Glycerin can be decreased when used in combination with Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Glycerin.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Glycerin.Approved, Investigational
WIN 55212-2The therapeutic efficacy of Glycerin can be decreased when used in combination with WIN 55212-2.Experimental
XipamideThe risk or severity of adverse effects can be increased when Xipamide is combined with Glycerin.Experimental
ZiconotideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Glycerin.Approved
ZonisamideThe therapeutic efficacy of Glycerin can be decreased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. Toxnet [Link]
  3. ChemIDplus [Link]
  4. DAILYMED [Link]
External Links
Human Metabolome Database
HMDB0000131
KEGG Drug
D00028
KEGG Compound
C00116
PubChem Compound
753
PubChem Substance
347827856
ChemSpider
733
ChEBI
17754
ChEMBL
CHEMBL692
PharmGKB
PA449783
HET
GOL
Wikipedia
Glycerol
ATC Codes
A06AG04 — GlycerolA06AX01 — Glycerol
AHFS Codes
  • 84:24.12 — Basic Ointments and Protectants
  • 56:12.00 — Cathartics and Laxatives
  • 40:36.00 — Irrigating Solutions
  • 48:01.00* — Other Cold and Cough Preparations
  • 36:89.00* — Other Diagnostics
PDB Entries
1ah8 / 1ahp / 1ayf / 1b4e / 1b6g / 1b8f / 1bcs / 1bf6 / 1bg4 / 1bhp
show 15070 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePsychology, Social1
1CompletedSupportive CareHealthy People / Healthy Volunteers1
1CompletedTreatmentDry Eye Syndrome (DES)1
1, 2CompletedTreatmentHypersensitivity / Hypersensitivity, Food / Hypersensitivity, Immediate / Peanut Hypersensitivity1
1, 2RecruitingTreatmentHeadache Disorders / Trigeminal Neuralgia (TN)1
2CompletedSupportive CareOccasional Constipation1
2CompletedSupportive CareOral Mucositis1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentThyroid Eye Disease1
2TerminatedTreatmentDry Eye Syndromes1
2, 3CompletedTreatmentConjunctivitis, Viral1
2, 3CompletedTreatmentEye Dryness1
3CompletedPreventionRadiation Dermatitis1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentBee Venom Allergy1
3CompletedTreatmentConjunctivitis, Viral1
3CompletedTreatmentDry Eye Syndrome (DES)1
3CompletedTreatmentDry Eye Syndromes1
3CompletedTreatmentExfoliation Syndrome / Glaucoma, Primary Open Angle (POAG)1
3CompletedTreatmentEye Dryness1
3CompletedTreatmentMeningitis, Bacterial1
3CompletedTreatmentOccasional Constipation1
3RecruitingPreventionLabour Pain1
3Unknown StatusTreatmentAdenovirus / Conjunctivitis1
4Active Not RecruitingPreventionObesity, Visceral1
4CompletedNot AvailableEndothelial Graft Rejection1
4CompletedDiagnosticColonoscopy1
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentConjunctivitis, Seasonal Allergic2
4CompletedTreatmentDry Eye Syndrome (DES)1
4CompletedTreatmentDry Eye Syndromes2
4CompletedTreatmentGlaucoma1
4CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4CompletedTreatmentOpen-angle Glaucoma (OAG)1
4RecruitingPreventionPancreatitis1
4RecruitingTreatmentDentin Hypersensitivity1
4RecruitingTreatmentDry Eye Syndromes1
4Unknown StatusDiagnosticEye Dryness1
4Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Occupational1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedNot AvailableDry Eye Syndrome (DES)2
Not AvailableCompletedBasic ScienceDiabetic Macular Edema (DME)1
Not AvailableCompletedBasic ScienceDry Eye Syndrome (DES)1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedDiagnosticInsulin Resistance1
Not AvailableCompletedPreventionEye Dryness1
Not AvailableCompletedScreeningColorectal Cancers1
Not AvailableCompletedSupportive CarePain2
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentEye Dryness1
Not AvailableCompletedTreatmentEye Dryness / Lipid Layer / Liposic / Tear Film / Tears Naturale Forte1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentIntraocular Pressure1
Not AvailableCompletedTreatmentKeratoconjunctivitis Sicca1
Not AvailableCompletedTreatmentMigraines1
Not AvailableRecruitingBasic ScienceCarnitine Palmitoyltransferase II Deficiency, Myopathic / Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency / Medium-chain Acyl-CoA Dehydrogenase Deficiency / Normal Volunteers / Trifunctional Protein Deficiency / Very Long-chain Acyl-CoA Dehydrogenase Deficiency1
Not AvailableRecruitingPreventionVery Low Birth Weight Infant1
Not AvailableRecruitingSupportive CarePain1
Not AvailableRecruitingTreatmentAdenoviral Conjunctivitis / Conjunctivitis1
Not AvailableRecruitingTreatmentAge-related Cataract1
Not AvailableRecruitingTreatmentEye Dryness1
Not AvailableRecruitingTreatmentFeeding Intolerance1
Not AvailableRecruitingTreatmentMeibomian Gland Dysfunction (MGD) / Sjögren's Syndrome2
Not AvailableUnknown StatusTreatmentHyperglycemias / Infant, Low Birth Weight1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical4 g/200mL
LiquidTopical13 mg/mL
LiquidTopical.19 g/6.5g
LiquidTopical.067 mL/2mL
SoapTopical15 g/100g
SolutionTopical10 g/100mL
PatchTopical1.84 g/23mL
SolutionTopical1.8 g/101
CreamCutaneous28 mL/140mL
CreamTopical.08 g/g
CreamTopical.07 mg/mL
LiquidTopical.08 mg/mL
SuppositoryRectal1.614 g/1
SuppositoryRectal2 g/1
CreamTopical11.55 g/55mL
CreamTopical24.6 g/120mL
CreamTopical12.1 g/55mL
KitOral; Topical
CreamTopical31.5 g/150mL
EmulsionOral
CreamTopical4 mg/mL
GelTopical6 mg/150mL
EmulsionTopical2.55 g/50mL
LiquidTopical1.9 g/50mL
GelTopical6.2 g/31mL
LiquidTopical5.2 g/200mL
GelTopical16 g/200mL
GelTopical
Aerosol, foamTopical.54 mg/mL
CreamTopical2.85 g/50g
SolutionTopical6.22 g/100mL
PatchTopical1.3 g/26mL
CreamTopical1.8 g/60mL
LiquidTopical4.5 g/150mL
CreamTopical5 g/25g
CreamTopical8.81 g/25g
CreamTopical8.006 g/100mL
LiquidTopical25 g/100g
CreamTopical5 g/50mL
SolutionTopical2.8 g/35mL
CreamTopical1.2 g/20mL
SolutionTopical1.65 g/120mL
CreamTopical3 g/30mL
PatchTopical1.89 g/27g
PatchTopical2.7 g/27g
PatchTopical7 g/100g
PatchTopical1.65 g/22mL
Injectable foamTopical12 g/120mL
PatchTopical1.5 g/25g
PatchTopical.8 g/8g
PatchTopical1.2 g/20g
CreamTopical1.8 g/9g
PatchTopical1.7 g/8.5g
CreamTopical.084 g/mL
PowderTopical.0000167 g/g
Solution / dropsAuricular (otic)
LotionTopical6 g/100mL
LotionTopical13 g/100mL
CreamTopical11 g/100mL
CreamTopical5 mg/50mL
CreamTopical4 mg/40mL
ShampooTopical3.075 g/100g
CreamTopical8.06 g/100g
GelTopical11.985 g/100g
LiquidTopical3.075 g/100mL
ShampooTopical3.845 g/100g
CreamTopical6.46 mg/100mL
SprayTopical.075 g/75mL
LiquidTopical10 g/100g
LiquidTopical3.1406 mL/200mL
CreamTopical4.9947 mL/50mL
SolutionTopical9.5 g/100mL
SolutionTopical11 g/100mL
LiquidTopical2.5 g/100g
PatchTopical1.75 g/25g
EmulsionTopical9.6 mg/120mL
SolutionTopical41.85 mg/150mL
SolutionTopical8.13 mg/150mL
CreamTopical1.21 mg/30mL
CreamTopical30 g/150mL
CreamTopical.9 g/30g
CreamTopical1.2 mg/10mL
LiquidTopical10.82 g/100mL
CreamTopical10.03 g/100g
PatchTopical1.92 mg/32mL
PatchTopical.6 g/20g
PatchTopical1.8 mg/30mL
LiquidTopical8.13 g/100g
GelTopical13.5 g/45g
LiquidTopical25 g/100mL
LiquidTopical6 mg/150mL
CreamTopical2.7 mg/90mL
SolutionTopical19.6 g/200mL
SprayTopical.5 g/50mL
PatchTopical.5 g/25mL
LiquidTopical4 g/100g
LiquidTopical5 g/100mL
CreamTopical2 g/100g
PowderTopical1.8 g/100mL
CreamTopical.15 g/100mL
CreamTopical5.0613 g/100mL
LotionTopical6.502 g/100mL
CreamTopical2.3315 g/100mL
LiquidTopical.1535 g/100mL
ShampooTopical.01 g/mL
PatchTopical9 g/51
CreamTopical10 g/50g
LotionTopical
LotionTopical2 g/100mL
GelTopical5 g/100g
LiquidTopical40 g/100mL
GelTopical.01 g/100mL
GelTopical.16 g/160mL
CreamTopical30.75 g/150mL
CreamTopical31.2 g/150mL
LotionTopical32.12 g/400mL
CreamTopical12.9 g/150mL
OintmentTopical5 g/100mL
SprayOral
LiquidOral
CreamTopical.012 g/100mL
LiquidTopical4 g/100mL
CreamTopical.7675 g/100g
CreamTopical6.5 g/100g
GelTopical15 g/150mL
CreamTopical3 mg/mL
LiquidTopical4.8 g/120mL
CreamTopical1.5 mg/30mL
LiquidOphthalmic
Solution / dropsOphthalmic2.5 mg/mL
Kit
CreamTopical200 mg/mL
CreamTopical.08 g/mL
LotionTopical.09 g/mL
LiquidTopical.08 g/mL
CreamTopical.0433 g/mL
CreamTopical.0279 g/mL
PatchTopical2.1 g/101
PatchTopical2.94 g/101
PatchTopical2.1 g/7.5g
CreamTopical6.88 mg/160mL
GelTopical5.6 mg/80mL
Kit
Injection, solutionIntradermal.525 mL/mL
LiquidTopical.04 mg/mL
LiquidTopical.08 g/g
CreamTopical1 g/100mL
PatchTopical.22 g/22g
PatchTopical.27 g/27g
SoapTopical.1 g/100g
CreamTopical7 mg/35mL
JellyEnteral19.312 g/48.28g
CreamTopical26 mg/130mL
ShampooTopical.001 g/100mL
EmulsionTopical10 g/100mL
GelTopical.2 g/100mL
LiquidRectal2.8 g/1
LiquidRectal5.4 g/1
LiquidTopical1 kg/20kg
CreamTopical15.585 g/100mL
LiquidTopical11.3 g/100mL
LiquidTopical20.009 g/100mL
CreamTopical11.0005 g/100mL
LiquidTopical10.05 g/100mL
CreamTopical10.0002 g/100mL
GelTopical91.16098 g/100mL
LiquidTopical26 g/200mL
GelTopical37.5 g/150mL
LiquidTopical30.78 mL/100mL
LiquidTopical1.6 g/100mL
LiquidTopical.2 g/100mL
CreamTopical4.073 g/100mL
LiquidTopical2.53 g/100g
CreamTopical1.77 g/50g
SprayTopical.13 g/100mL
CreamTopical1.9 g/30g
LiquidTopical6 g/100g
LiquidTopical10.01 g/100mL
LotionTopical2 mL/40mL
GelTopical3.75 g/15g
GelTopical.5 g/2g
Paste, dentifriceDental7.68 g/120g
EmulsionTopical
Solution / dropsTopical
GelTopical9.6 g/120mL
GelTopical.57 g/100mL
GelTopical5.088 mL/100mL
CreamTopical1.729 g/100g
KitTopical
LiquidTopical5.006 g/100mL
CreamTopical.04 g/mL
LiquidTopical2.53045 g/100g
CreamTopical7.05 g/100mL
LiquidTopical8.05 g/100mL
LiquidTopical1 g/100mL
CreamTopical4.07 g/100mL
LiquidTopical4.04 g/100mL
GelTopical4 g/100mL
CreamCutaneous
LiquidTopical.5 g/100mL
CreamTopical8 g/100mL
CreamTopical5 g/100mL
LiquidTopical3 g/100mL
CreamTopical6.1000565 g/100mL
LiquidTopical7.1270547 g/100mL
CreamTopical3 g/100mL
LiquidTopical16 g/100mL
LiquidTopical10 g/100mL
LiquidTopical6 g/100mL
LiquidTopical4.044 g/100mL
LiquidTopical.0125 g/mL
CreamTopical6.3 g/18g
PatchTopical35 1/18g
GelTopical1 g/100mL
PatchTopical1 g/100g
KitOral; Topical
KitBuccal; Topical
SwabTopical200 mg/.5mL
LiquidAuricular (otic)
PatchTopical1.3 g/25mL
LiquidTopical4.8 g/160mL
GelTopical14.4 g/120mL
GelTopical24 g/120mL
SolutionTopical4.97 mg/mL
CreamTopical1 g/25mL
PatchTopical1.75 mg/101
LiquidTopical10.87 g/100mL
LiquidTopical4.102 g/100mL
LotionTopical10.2 g/100mL
LiquidTopical12 g/100g
LotionTopical5 g/100mL
CreamTopical.025 g/100g
PatchTopical10 g/100g
LiquidTopical20 g/100g
GelTopical30 g/100mL
GelTopical5 g/100mL
SprayTopical5 g/100mL
LiquidTopical.935 g/100mL
CreamTopical53.67 g/250mL
CreamTopical4 g/20mL
LotionTopical35 mg/mL
SolutionOphthalmic1 g/100g
CreamTopical2 g/100mL
LiquidTopical12 g/100mL
LiquidTopical.01 g/100mL
CreamTopical.01 g/100mL
LiquidTopical.0798 g/mL
LiquidTopical11 g/100mL
LiquidTopical1 g/100g
CreamTopical4 g/100mL
CreamTopical10.5 mg/mL
CreamTopical31.65 g/155mL
CreamTopical8.15 g/40mL
CreamRectal; Topical25 g/100mL
GelTopical30 mL/150mL
LiquidTopical.02 g/2mL
CreamTopical29 mg/145mL
GelTopical20 g/100g
PatchTopical70.4 mg/1
CreamTopical1.25 mg/25mL
GelTopical41.85 g/150mL
PatchTopical3.36 g/51
PatchTopical3.36 g/101
PatchTopical3.36 mg/32mL
CreamTopical4.83 g/23mL
CreamTopical4.6 g/23mL
SprayTopical.5 mg/mL
LiquidOral
LiquidTopical995 mg/mL
SuppositoryRectal1.3 g/1
SuppositoryRectal1.2 g/1
SuppositoryRectal2.1 g/1
LiquidTopical100 %
LiquidOral; Topical
LiquidRectal12.5 g/1
SuppositoryRectal2.09 g
SuppositoryRectal1 g
SuppositoryRectal90 %
LiquidOral; Topical100 %
CreamRectal; Topical
LiquidIntradermal; Subcutaneous
LiquidOral100 %
SuppositoryRectal91 %
InjectionCutaneous; Intradermal; Subcutaneous.53 g/mL
SolutionUnknown
GelTopical.5 mg/mL
LiquidTopical100 mg/mL
CreamTopical10.20052486 g/100g
CreamTopical
SolutionTopical8.7 g/145mL
CreamTopical6.5 g/130mL
CreamTopical11.7 g/130mL
CreamTopical10 g/100g
CreamTopical1.07 g/20mL
CreamTopical10 g/100mL
LotionTopical3 g/100mL
LiquidTopical7 g/100mL
SolutionTopical4 mg/mL
ShampooTopical3.88 mg/mL
CreamTopical28 %
LiquidTopical30 g/150mL
LiquidTopical9 g/300mL
SolutionTopical15.96 g/120mL
SprayTopical.4 g/40mL
CreamTopical.1 g/100mL
CreamTopical.1 g/100g
ShampooTopical.2 g/100mL
CreamTopical4 g/50mL
EmulsionTopical12 g/120mL
LotionTopical10.5 g/150mL
SprayTopical12 g/150mL
SprayTopical7.2 g/120mL
CreamTopical3.5 g/50mL
CreamTopical2.5 g/50mL
LiquidTopical2.00008 g/100mL
CreamTopical11 mg/mL
CreamTopical13 mg/mL
CreamTopical8 mg/mL
LiquidTopical5.740794 g/100mL
CreamTopical.175 mg/5mL
LiquidTopical.0001 g/mL
LiquidTopical.01 g/mL
EmulsionTopical.034 g/mL
LiquidTopical.04 g/mL
EmulsionTopical.02 g/mL
Solution / dropsOphthalmic1 g/100mL
LiquidTopical2.5 g/250mL
LotionTopical8 g/200mL
CreamTopical1.67 mg/33mL
CreamTopical.66 mg/33mL
PatchTopical20 g/100g
GelVaginal.04 g/g
LiquidTopical15 g/100mL
SolutionVaginal6 g/100g
CreamTopical31 mg/155mL
CreamTopical11.57 mg/50mL
CreamTopical9 mg/45mL
LiquidTopical.8 mg/81
LotionTopical28 mg/140mL
CreamTopical5 mg/25mL
PatchTopical5 g/25g
LiquidTopical28 mg/140mL
LiquidTopical11 g/100g
LiquidTopical9 g/100g
LiquidTopical8 g/100g
CreamTopical8 g/100g
PowderTopical.1 g/g
LiquidTopical.002 g/mL
SwabTopical.25 g/2.5mL
PatchTopical2.5 g/25mL
LiquidTopical.3 g/1.5mL
PatchTopical1.08 g/27mL
LiquidTopical.1 g/1.5mL
CreamTopical.06 g/1.5mL
PatchTopical1.61 g/30mL
LiquidTopical.2 g/1.5mL
PatchTopical1 g/25mL
GelTopical5.5 g/100mL
LiquidTopical10.013 g/100mL
CreamTopical8.013 g/100mL
LiquidTopical5 g/100g
LiquidTopical3.2 g/100mL
LiquidTopical3 g/100g
LiquidTopical4.001 g/100mL
CreamTopical18 g/100mL
GelTopical11 g/100mL
CreamTopical8.001 g/100mL
LiquidTopical3.02 g/100mL
LiquidTopical5.5 g/100mL
LiquidVaginal7 g/100mL
LiquidTopical2 g/100mL
GelTopical2 g/100g
ShampooTopical4 g/100mL
LiquidTopical2.5 g/100mL
CreamTopical1.5 g/100mL
OilTopical1 g/100mL
LiquidTopical4.2 g/100mL
GelTopical1.5 g/100mL
CreamRectal
GelTopical6.59 g/10mL
GelTopical8.99 g/10mL
GelTopical2 g/10mL
GelTopical2.01 g/10mL
CreamTopical.579998 g/100mL
SwabOral7.5 1/1
SwabOral7.5 g/100g
SwabOral7.5 mL/100mL
SwabTopical.43 mL/10mL
SwabTopical500 mg/mL
SwabTopical7.5 g/100g
SolutionTopical1.94 mg/60mL
CreamTopical30 mg/mL
CreamTopical.4 mg/40mL
CreamTopical20 g/100g
CreamTopical10 mg/mL
OintmentTopical40 mg/g
SoapTopical12 g/60g
PatchTopical
LiquidTopical8.7675 g/100g
PatchTopical.34 g/17g
GelTopical3 g/100mL
LiquidTopical.04 g/g
LiquidTopical4.001 g/100g
CreamTopical.00007 g/mL
CreamTopical.02 g/mL
CreamTopical.00001 mg/mL
PatchTopical2 g/10g
LiquidTopical.24 g/8mL
LiquidTopical.5 mg/mL
SprayOral29.5 mg/mL
PowderTopical
CreamTopical.10295 g/mL
ShampooTopical2 g/100mL
SwabOral.075 g/1
PatchTopical.13 g/3g
GelTopical4.8 g/120mL
PatchTopical.14 g/7g
EnemaRectal80 mL/100mL
LiquidTopical.0224 g/mL
PatchTopical.16 g/1.6g
PatchTopical3 g/101
LiquidTopical.01 g/g
CreamTopical4.2 g/100g
SprayTopical4.8 g/80mL
LotionTopical15 g/300mL
CreamTopical2.005 g/100mL
GelVaginal4 g/100g
LiquidTopical.05205 g/mL
EmulsionTopical.075205 g/mL
CreamTopical11.45 g/50mL
LiquidTopical2 g/100g
PasteOral
SolutionTopical6 g/100mL
GelTopical10 g/200mL
CreamTopical8.6 g/200mL
EmulsionTopical9 g/150mL
LiquidTopical.15 g/150mL
LiquidPercutaneous50 %
GelDental
SoapTopical1 g/100g
LiquidTopical8.75 g/100g
EmulsionTopical.8 g/100mL
CreamTopical.29 g/30mL
CreamTopical1.4 g/50mL
CreamTopical1.97 g/30mL
CreamTopical3.14 g/50mL
ShampooTopical7.5 g/300g
Solution / dropsOphthalmic2 g/1000mL
Solution / dropsOphthalmic.25 g/100mL
Solution / dropsOphthalmic.22 g/100mL
LotionTopical16 mg/200mL
LiquidTopical10.5 g/100g
LiquidTopical4.975 g/100mL
LiquidTopical19.91 g/100g
SoapTopical12 g/100g
LiquidTopical1.01 mg/2.8mL
LiquidTopical.58 mg/2.8mL
PatchTopical5.56 mg/27mL
LiquidTopical.57 mg/2.8mL
PatchTopical5.55 mg/27mL
GelTopical180 mg/g
SoapTopical8 g/100g
SolutionTopical
SolutionTopical69.8 g/100mL
SuppositoryRectal1 g/1
CreamTopical.5 mg/mL
LiquidTopical.29 g/5mL
EmulsionTopical3.5 mg/35mL
LiquidTopical30 g/100g
LiquidTopical2.145 g/100g
LiquidTopical3.055 g/100g
LiquidTopical3.005 g/100g
SolutionTopical7.35 g/30mL
LiquidOral5 g/100g
LiquidOral2 g/100mL
CreamOral5.05 g/100mL
LotionTopical20 mg/100mL
CreamTopical24 g/120g
LotionTopical.5 g/200mL
LotionTopical3.38 g/200mL
LotionTopical1.22 g/200mL
LotionTopical6.84 g/180mL
CreamTopical37.8 g/180mL
CreamTopical7 g/35mL
LiquidTopical.05 g/mL
LiquidTopical7 g/100g
SolutionTopical2.37 g/40mL
GelTopical9 g/100mL
LiquidOral4.5 mg/100mL
CreamTopical7 g/100mL
EmulsionTopical6 g/100mL
InjectionIntravenous
SprayTopical.5 g/100mL
PatchTopical7.5 g/30g
LotionTopical4 g/100mL
CreamTopical1.2 g/100mL
SolutionOphthalmic
ShampooTopical.02 mg/mL
LiquidTopical.19 g/8g
LiquidTopical.8 g/100g
CreamTopical.05 g/100g
CreamTopical2.92 mg/50mL
EmulsionTopical2.35 mg/125mL
CreamTopical2.55 mg/50mL
GelTopical9.6 mg/160mL
LiquidTopical7.81 mg/150mL
SoapTopical5 g/100g
ClothTopical
CreamTopical28 g/140mL
GelTopical15 g/150g
EmulsionOphthalmic
SolutionTopical2.6 g/40mL
SolutionTopical.21 mg/121
CreamTopical2.53 mg/150mL
CreamTopical1.87 mg/150mL
CreamTopical.25 g/20mL
CreamTopical7.8 mg/mL
CreamTopical1.98 mg/mL
CreamTopical.25 mg/mL
PatchTopical.8 g/16mL
PatchTopical.56 g/14mL
PatchTopical.33 g/3mL
PatchTopical2 g/25mL
CreamTopical2.04 g/30mL
GelTopical3.002 g/100mL
LiquidTopical.100005 g/g
LiquidTopical.03 mg/mL
LiquidNasal
LiquidTopical15 g/100g
LiquidTopical4 g/200mL
PatchTopical1.5 g/50g
CreamTopical.03 g/mL
LiquidTopical.06 g/mL
CreamTopical.03 g/g
LiquidTopical.03 g/g
PatchTopical.05 g/mL
LiquidTopical.07 g/mL
LiquidTopical.02 g/mL
CreamTopical.9 g/9g
CreamTopical.02 g/g
LiquidTopical.018 mg/mL
CreamTopical.000001 g/g
SoapTopical.5 g/100g
CreamTopical6 g/100mL
LotionTopical.4 g/100mL
SoapTopical.4 g/100g
CreamTopical15 mg/100mL
CreamTopical10 mg/100mL
PatchTopical6 g/100g
GelTopical5 mg/mL
GelTopical13.8 mg/100mL
GelTopical2.661 g/100mL
GelTopical.02 g/100mL
LiquidTopical.1 g/100mL
CreamTopical5.05 g/100g
PatchTopical2.1 g/7g
CreamTopical1.33 mg/30mL
LiquidTopical
SprayTopical
CreamCutaneous19.2 g/48g
CreamCutaneous16.8 g/48g
CreamTopical2.49 mL/50mL
CreamTopical9 g/75mL
LotionTopical7.5 g/150mL
LotionTopical6 g/120mL
CreamTopical1.69 mg/60mL
PatchTopical.8 g/101
LiquidTopical5.92 g/150mL
CreamTopical3.3 g/50g
CreamTopical5.82 g/60mL
PatchTopical1.96 g/28g
LiquidTopical13.5 g/150mL
CreamTopical3.5 g/70g
CreamTopical4.2 g/20g
CreamTopical6 g/30mL
GelTopical5 g/25g
PatchTopical1.37 mg/101
CreamTopical10 g/50mL
Solution / dropsOphthalmic
CreamTopical36 g/160mL
GelTopical60 g/300mL
GelTopical146.88 g/300mL
CreamTopical5.15 mL/100mL
CreamTopical5.6 g/50g
Injection, solutionIntradermal; Subcutaneous
Injection, solutionIntradermal; Subcutaneous.5 mL/mL
LiquidTopical.16 g/mL
CreamTopical1.6 mg/80mL
GelTopical4.65 mg/155mL
CreamTopical8 g/40mL
LiquidTopical.03 g/mL
SoapTopical
SolutionIrrigation2.6 %
PatchTopical1.84 g/23g
ShampooTopical.04 g/mL
CreamTopical6 g/30g
CreamTopical4.03 g/100mL
LiquidTopical1.001 g/100mL
SolutionTopical.12 mg/101
LiquidTopical6 g/200mL
Injectable foamTopical16.5 g/150mL
CreamTopical10.16 g/40mL
CreamTopical18 g/90mL
ShampooTopical2 g/100g
CreamTopical24 g/80g
LotionTopical12742.339 mg/145mL
CreamTopical5926.7425 mg/35mL
CreamTopical5.05 g/50g
LotionTopical8377.386 mg/60mL
Injectable foamTopical
CreamTopical1 g/45g
CreamTopical78.1 g/95g
GelTopical.252 g/45g
CreamTopical5.04 g/30mL
LiquidTopical5287.8 mg/140mL
CreamTopical2.1 g/70g
CreamTopical3147.5 mg/50mL
PatchTopical1.5 g/30g
CreamTopical4910.1 mg/50mL
EmulsionTopical9694.3 mg/140mL
LotionTopical503 mg/50mL
CreamTopical1510.8 mg/140mL
LiquidTopical1762.6 mg/140mL
LiquidTopical14100.8 mg/140mL
LotionTopical.008 g/100mL
LiquidTopical3.5 g/100mL
CreamTopical32.7 g/150mL
CreamTopical.1 g/g
LiquidTopical.1 g/mL
LiquidTopical.02 mg/mL
LiquidTopical.015 g/mL
SolutionTopical12.3 g/100mL
CreamTopical.06 g/mL
LiquidTopical.04 g/5mL
LiquidTopical1.005 g/100g
LiquidTopical.01 mg/mL
GelTopical2 g/100mL
GelTopical15 g/100mL
LotionTopical8.28 g/180mL
CreamTopical.05 g/mL
LiquidTopical.001 g/mL
CreamTopical.04 g/g
GelTopical.015 g/mL
CreamTopical5 mg/mL
LiquidTopical.06 g/g
CreamTopical3.43 g/50mL
LiquidTopical2.59 g/150mL
GelTopical91.16 g/100mL
GelTopical91.16098 g/100g
CreamTopical5 g/100g
CreamTopical4 g/100g
SuppositoryRectal83 g/100g
CreamTopical6 mg/150mL
PatchTopical2.3 g/23mL
ExtractTopical13.226 g/100mL
PatchTopical10 g/100mL
CreamTopical.2 g/100mL
EmulsionTopical2.04 g/100mL
CreamTopical6.2 g/100mL
ConcentrateTopical7 g/100mL
GelVaginal.17 g/g
GelVaginal.306 g/101
GelVaginal.11 g/101
PatchTopical1.57 g/35g
LotionTopical23 %
SuppositoryRectal2.145 g
GelTopical3.55 g/100mL
KitTopical
CreamTopical12.6 g/100mL
GelTopical9.7 g/100mL
LiquidTopical.3 g/100mL
GelTopical8.752 g/100mL
GelVaginal.1 g/100mL
LiquidVaginal.5 g/100mL
ShampooTopical2.5 g/100mL
SolutionTopical.25 g/5mL
CreamTopical.16 g/8g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1170.0 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.8ChemAxon
logS1.1ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity20.52 m3·mol-1ChemAxon
Polarizability8.93 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0fr2-0910000000-6497c0870b71585c6322
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0ktb-0920000000-93408d69acffad6f48af
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-05mk-0940000000-778ba583836705f8fdf4
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-00kb-0920000000-2e4b358941c660851f0a
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00dj-6920000000-6828d7b00cb31e84fac1
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0le9-0940000000-e0b9bada9be26d720326
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01ox-9000000000-3fe0c184a891364773a8
GC-MS Spectrum - EI-BGC-MSsplash10-0fr2-0930000000-470b6694b25fde40d80f
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0fr2-0910000000-6497c0870b71585c6322
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0ktb-0920000000-93408d69acffad6f48af
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-05mk-0940000000-778ba583836705f8fdf4
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kb-0920000000-2e4b358941c660851f0a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00dj-6920000000-6828d7b00cb31e84fac1
GC-MS Spectrum - GC-MSGC-MSsplash10-0le9-0940000000-e0b9bada9be26d720326
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kb-0920000000-085a71f40d38f2729036
Mass Spectrum (Electron Ionization)MSsplash10-01ox-9000000000-3706109441e6d3017895
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-0a4i-9000000000-d7c139dc01453f61eb99
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-0a4l-9000000000-7d7844b4813b038012da
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0udi-9100000000-16029dbe79f139ab904a
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-01ox-9000000000-3fe0c184a891364773a8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-a638e26fe3c3f48563c2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004l-9000000000-d3fd9e9abd911eb0f88e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-9000000000-ca218dca3a5d86196d81
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-b40367f5ca8d11288fbe
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-ba29a0647084e32d8704
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0abc-9000000000-4cd85379d414c16f95c0
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar alcohols
Alternative Parents
Secondary alcohols / Polyols / Primary alcohols / Hydrocarbon derivatives
Substituents
Sugar alcohol / Secondary alcohol / Polyol / Hydrocarbon derivative / Primary alcohol / Alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
triol, alditol (CHEBI:17754) / Glycerols (C00116) / a sugar alcohol (GLYCEROL)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. ChEMBL [Link]
  2. UniProt [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the con...
Gene Name
HPGDS
Uniprot ID
O60760
Uniprot Name
Hematopoietic prostaglandin D synthase
Molecular Weight
23343.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Clostridium cellulolyticum (strain ATCC 35319 / DSM 5812 / JCM 6584 / H10)
Pharmacological action
Unknown
General Function
Cellulose binding
Specific Function
The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes: (1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases th...
Gene Name
celCCG
Uniprot ID
P37700
Uniprot Name
Endoglucanase G
Molecular Weight
79775.34 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phospholipase a2 activity
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name
PLA2G2E
Uniprot ID
Q9NZK7
Uniprot Name
Group IIE secretory phospholipase A2
Molecular Weight
15988.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inositol-3-phosphate synthase activity
Specific Function
Key enzyme in myo-inositol biosynthesis pathway that catalyzes the conversion of glucose 6-phosphate to 1-myo-inositol 1-phosphate in a NAD-dependent manner. Rate-limiting enzyme in the synthesis o...
Gene Name
ISYNA1
Uniprot ID
Q9NPH2
Uniprot Name
Inositol-3-phosphate synthase 1
Molecular Weight
61067.285 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Ensifer meliloti
Pharmacological action
Unknown
General Function
Sequence-specific dna binding
Specific Function
Member of the two-component regulatory system DctB/DctD involved in the transport of C4-dicarboxylates. When activated by DctB acts in conjunction with sigma-54 to activate the transcription of dctA.
Gene Name
dctD
Uniprot ID
P13632
Uniprot Name
C4-dicarboxylate transport transcriptional regulatory protein DctD
Molecular Weight
50060.805 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH1B
Uniprot ID
P00325
Uniprot Name
Alcohol dehydrogenase 1B
Molecular Weight
39854.21 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol binding
Specific Function
Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. Involved in the regulation of epithelial secretion of elect...
Gene Name
ITPR1
Uniprot ID
Q14643
Uniprot Name
Inositol 1,4,5-trisphosphate receptor type 1
Molecular Weight
313926.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Small molecule binding
Specific Function
This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.
Gene Name
PAEP
Uniprot ID
P09466
Uniprot Name
Glycodelin
Molecular Weight
20624.015 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids.
Gene Name
NAGA
Uniprot ID
P17050
Uniprot Name
Alpha-N-acetylgalactosaminidase
Molecular Weight
46564.15 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Pseudomonas stutzeri
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Diheme, high potential cytochrome c believed to be an intermediate electron donor to terminal oxidation systems.
Gene Name
cc4
Uniprot ID
Q52369
Uniprot Name
Cytochrome c4
Molecular Weight
21741.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Desulfovibrio desulfuricans (strain ATCC 27774 / DSM 6949)
Pharmacological action
Unknown
General Function
Ferroxidase activity
Specific Function
Iron-storage protein, whose ferroxidase center binds Fe(2+) ions, oxidizes them by dioxygen to Fe(3+), and participates in the subsequent Fe(3+) oxide mineral core formation within the central cavi...
Gene Name
bfr
Uniprot ID
Q93PP9
Uniprot Name
Bacterioferritin
Molecular Weight
19881.14 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Type iii transforming growth factor beta receptor binding
Specific Function
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Tran...
Gene Name
TGFBR2
Uniprot ID
P37173
Uniprot Name
TGF-beta receptor type-2
Molecular Weight
64567.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Atp binding
Specific Function
Not Available
Gene Name
argG
Uniprot ID
P0A6E4
Uniprot Name
Argininosuccinate synthase
Molecular Weight
49898.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Enterococcus hirae
Pharmacological action
Unknown
General Function
Phosphopyruvate hydratase activity
Specific Function
Catalyzes the reversible conversion of 2-phosphoglycerate into phosphoenolpyruvate. It is essential for the degradation of carbohydrates via glycolysis.
Gene Name
eno
Uniprot ID
Q8GR70
Uniprot Name
Enolase
Molecular Weight
46410.935 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor signaling protein activity
Specific Function
GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modula...
Gene Name
ARF1
Uniprot ID
P84077
Uniprot Name
ADP-ribosylation factor 1
Molecular Weight
20696.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
Pharmacological action
Unknown
General Function
Drug transmembrane transporter activity
Specific Function
The periplasmic linker component of the MexAB-OprM efflux system that confers multidrug resistance. Also functions as the major efflux pump for n-hexane and p-xylene efflux. Over-expression of the ...
Gene Name
mexA
Uniprot ID
P52477
Uniprot Name
Multidrug resistance protein MexA
Molecular Weight
40969.34 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sulfate adenylyltransferase (atp) activity
Specific Function
Bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two steps in the sulfate activation pathway. The first step is the transfer of a sulfate group to ATP to yield ...
Gene Name
PAPSS1
Uniprot ID
O43252
Uniprot Name
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1
Molecular Weight
70832.725 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Catalyzes the sequential NAD-dependent oxidations of L-histidinol to L-histidinaldehyde and then to L-histidine.
Gene Name
hisD
Uniprot ID
P06988
Uniprot Name
Histidinol dehydrogenase
Molecular Weight
46109.815 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Mismatched dna binding
Specific Function
This protein is involved in the repair of mismatches in DNA. It is required for dam-dependent methyl-directed DNA mismatch repair. May act as a "molecular matchmaker", a protein that promotes the f...
Gene Name
mutL
Uniprot ID
P23367
Uniprot Name
DNA mismatch repair protein MutL
Molecular Weight
67923.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Water channel activity
Specific Function
Transporter of glycerol across the cytoplasmic membrane, with limited permeability to water and small uncharged compounds such as polyols.
Gene Name
glpF
Uniprot ID
P0AER0
Uniprot Name
Glycerol uptake facilitator protein
Molecular Weight
29779.71 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor
Specific Function
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. R2 contains the tyrosyl radical required for catalysis.
Gene Name
nrdB
Uniprot ID
P69924
Uniprot Name
Ribonucleoside-diphosphate reductase 1 subunit beta
Molecular Weight
43516.885 Da
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Adenine glycosylase active on G-A mispairs. MutY also corrects error-prone DNA synthesis past GO lesions which are due to the oxidatively damaged form of guanine: 7,8-dihydro-8-oxoguanine (8-oxo-dG...
Gene Name
mutY
Uniprot ID
P17802
Uniprot Name
Adenine DNA glycosylase
Molecular Weight
39148.835 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Trna methyltransferase activity
Specific Function
Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).
Gene Name
TRDMT1
Uniprot ID
O14717
Uniprot Name
tRNA (cytosine(38)-C(5))-methyltransferase
Molecular Weight
44596.17 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Retinal dehydrogenase activity
Specific Function
Binds free retinal and cellular retinol-binding protein-bound retinal. Can convert/oxidize retinaldehyde to retinoic acid (By similarity).
Gene Name
ALDH1A1
Uniprot ID
P00352
Uniprot Name
Retinal dehydrogenase 1
Molecular Weight
54861.44 Da
References
  1. UniProt [Link]
  2. ChEMBL [Link]
  3. KEGG [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on November 30, 2015 12:10 / Updated on August 14, 2018 04:32